17 September 2015
EMA/347054/2015
Stakeholders and Communication Division

Agenda - EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting

17 September 2015, 08:45hrs to 17:00hrs – meeting room: 3E

Co-Chairs: I. Moulon (EMA), D. Haerry (PCWP), G. Calvo (HCPWP)

Activity		Action	Speaker
08:30	Registration and reimbursement arrangements		
08:45	Welcome and introduction / health and safety information Disclosure of interests / adoption of the agenda		I. Moulon (EMA)
1. Benefit/Risk research			
09:00	1.1 Follow up from PROTECT project; results from VISUALIZE (benefit/risk) research study	For information	A. Beyer (University of Groningen)
2. EMA initiatives and ongoing activities			
09:40	2.1 Need for collaboration in pharmacovigilance to ensure effective health protection and promotion	For discussion	J. Bouvy / P. Arlett (EMA)
	2.2 New pharmacovigilance systems and services	For information	P. Arlett (EMA)
10:30	*Coffee Break*		
10:45	2.3 Clinical Trial regulation transparency update	For information	F. Sweeney (EMA)

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

11:15	2.4 Enhanced early dialogue to foster development and facilitate accelerated assessment	For information	Z. Hanaizi / J. Llinares (EMA)
12:00	*Lunch*		
3. Committee / working party feedback			
13:00	3.1 Feedback from scientific committees 3.2 Overview of HMPC; tasks and responsibilities	For information/ discussion	Committee members
13:45	3.3 Progress report from PCWP and HCPWP topics groups	For information/ discussion	PCWP/HCPWP co-leads
14:30	*Coffee Break*		
14:45	3.4 PCWP and HCPWP work programmes for 2016	For agreement	I. Silva and N. Bere (EMA)
15:15	3.5 Reminder new eligibility criteria and new working party mandates	For information	I. Silva and N. Bere (EMA)
15:30	3.6 Results of survey to national competent authorities	For information/ discussion	M. Mavris (EMA)
4. Members voice: sharing practices			
16:00	4.1 Improving multiple sclerosis management in Europe: better outcomes with better data	For information	C. Thalheim (EMSP)
16:30	4.2 European consortium study on the availability of anti-neoplastic medicines	For information	A. Eniu (ESMO)
5. AOB			
17:00	*End of meeting*		